{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:31:28Z","timestamp":1792679488910,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T00:00:00Z","timestamp":1584576000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T00:00:00Z","timestamp":1584576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100017183","name":"Janssen Scientific Affairs, LLC","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017183","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s12325-020-01276-3","type":"journal-article","created":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T19:03:38Z","timestamp":1584644618000},"page":"2127-2143","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Persistence, Dose Titration, and Health Care Resource Utilization Among Crohn\u2019s Disease Patients Treated With Ustekinumab: A Real-World Analysis in the United States"],"prefix":"10.1007","volume":"37","author":[{"given":"Camilo","family":"Obando","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijie","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Muser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neel","family":"Vaidya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqin","family":"Qiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Mallampati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,19]]},"reference":[{"key":"1276_CR1","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/ajg.2018.27","volume":"113","author":"GR Lichtenstein","year":"2018","unstructured":"Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG clinical guideline: management of Crohn\u2019s disease in adults. Am J Gastroenterol. 2018;113:481\u2013517.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"1276_CR2","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/gut.49.6.777","volume":"49","author":"E Louis","year":"2001","unstructured":"Louis E, Collard A, Oger AF, et al. Behaviour of Crohns disease according to the Vienna classification: changing pattern over the course of the disease. Gut. 2001;49(6):777\u201382. https:\/\/doi.org\/10.1136\/gut.49.6.777.","journal-title":"Gut"},{"issue":"7","key":"1276_CR3","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.mayocp.2017.04.010","volume":"92","author":"JD Feuerstein","year":"2017","unstructured":"Feuerstein JD, Cheifetz A. Crohn disease: epidemiology, diagnosis and management. Mayo Clin Proc. 2017;92(7):1088\u2013103.","journal-title":"Mayo Clin Proc"},{"key":"1276_CR4","unstructured":"Crohn\u2019s & Colitis Foundation of America (CCFA). The facts about inflammatory bowel diseases. 2014. http:\/\/www.crohnscolitisfoundation.org\/assets\/pdfs\/updatedibdfactbook.pdf. Accessed 9 Aug 2018."},{"key":"1276_CR5","doi-asserted-by":"crossref","unstructured":"Nguyen GC, Chong CA, Chong RY. National estimates of the burden of inflammatory bowel disease among racial and ethnic groups in the United States. J Crohns Colitis. 2014; 2014:288\u2013295.","DOI":"10.1016\/j.crohns.2013.09.001"},{"issue":"9","key":"1276_CR6","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1046\/j.1365-2036.2002.01323.x","volume":"16","author":"RD Cohen","year":"2002","unstructured":"Cohen RD. The quality of life in patients with Crohn\u2019s disease. Aliment Pharmacol Ther. 2002;16(9):1603\u20139.","journal-title":"Aliment Pharmacol Ther"},{"key":"1276_CR7","doi-asserted-by":"crossref","unstructured":"Kappelman MD, Porter CQ, Galanko JA, Rifas-Shiman SL, Ollendorf DA, Sandler RS, Finkelstein JA. Utilization of healthcare resources by US children and adults with inflammatory bowel disease. Inflamm Bowel Dis. 2011; 17(1):62\u20138.","DOI":"10.1002\/ibd.21371"},{"key":"1276_CR8","doi-asserted-by":"publisher","unstructured":"Peery AF, Dellon ES, Lund J, et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology. 2012;143(5). https:\/\/doi.org\/10.1053\/j.gastro.2012.08.002.","DOI":"10.1053\/j.gastro.2012.08.002"},{"issue":"3","key":"1276_CR9","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/s0002-9270(01)02234-1","volume":"96","author":"S Hanauer","year":"2001","unstructured":"Hanauer S, Sandborn W. Management of Crohns disease in adults. Am J Gastroenterol. 2001;96(3):635\u201343. https:\/\/doi.org\/10.1016\/s0002-9270(01)02234-1.","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"1276_CR10","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1155\/2002\/463015","volume":"16","author":"R Hilsden","year":"2002","unstructured":"Hilsden R. Funding the new biologics\u2014what can we learn from infliximab? The CCOHTA report: a gastroenterologist\u2019s viewpoint. Can J Gastroenterol. 2002;16(12):865\u20138.","journal-title":"Can J Gastroenterol."},{"issue":"5","key":"1276_CR11","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1053\/j.gastro.2007.03.024","volume":"132","author":"SR Targan","year":"2007","unstructured":"Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, et al. Natalizumab for the treatment of active Crohn\u2019s disease: Results of the ENCORE trial. Gastroenterology. 2007;132(5):1672\u201383. https:\/\/doi.org\/10.1053\/j.gastro.2007.03.024.","journal-title":"Gastroenterology"},{"issue":"9","key":"1276_CR12","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/j.clinthera.2018.07.013","volume":"40","author":"J Brady","year":"2018","unstructured":"Brady J, Stott-Miller M, Mu G, Perera S. Treatment patterns and sequencing in patients with inflammatory bowel disease. Clin Ther. 2018;40(9):1509\u201321.","journal-title":"Clin Ther"},{"key":"1276_CR13","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2147\/CEG.S109696","volume":"9","author":"F Lelli","year":"2016","unstructured":"Lelli F, Nuhoho S, Lee XY, Xu W. Systematic review: treatment pattern and clinical effectiveness and safety of pharmaceutical therapies for Crohn\u2019s disease in Europe. Clin Exp Gastroenterol. 2016;9:311\u201323.","journal-title":"Clin Exp Gastroenterol"},{"issue":"7","key":"1276_CR14","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/apt.13083","volume":"41","author":"J Gisbert","year":"2015","unstructured":"Gisbert J, Marin A, McNicholl A, Chaparro M. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment Pharmacol Ther. 2015;41(7):613\u201323.","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"1276_CR15","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1007\/s10620-018-5385-9","volume":"64","author":"N Gordon","year":"2019","unstructured":"Gordon N, Sebastian S. Real-world success of biologic therapy in IBD: no more reasons to be anti antibody. Dig Dis Sci. 2019;64(3):614\u20135.","journal-title":"Dig Dis Sci"},{"issue":"7","key":"1276_CR16","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJMoa020888","volume":"348","author":"F Baert","year":"2003","unstructured":"Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease. N Engl J Med. 2003;348(7):601\u20138.","journal-title":"N Engl J Med"},{"issue":"1","key":"1276_CR17","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1093\/gastro\/gou087","volume":"3","author":"A Moss","year":"2015","unstructured":"Moss A. Optimizing the use of biological therapy in patients with inflammatory bowel disease. Gastroenterol Rep. 2015;3(1):63\u20138.","journal-title":"Gastroenterol Rep."},{"issue":"10","key":"1276_CR18","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1111\/apt.12727","volume":"39","author":"D Rubin","year":"2014","unstructured":"Rubin D, Mody R, Davis K, Wang C. Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn\u2019s disease. Aliment Pharmacol Ther. 2014;39(10):1143\u201355.","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"1276_CR19","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1002\/ibd.22925","volume":"18","author":"D Rubin","year":"2012","unstructured":"Rubin D, Uluscu O, Sederman R. Response to biologic therapy in Crohn\u2019s disease is improved with early treatment: an analysis of health claims data. Inflamm Bowel Dis. 2012;18(12):2225\u201331.","journal-title":"Inflamm Bowel Dis"},{"issue":"9","key":"1276_CR20","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1111\/j.1365-2036.2011.04612.x","volume":"33","author":"S Ben-Horin","year":"2011","unstructured":"Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn\u2019s disease. Aliment Pharmacol Ther. 2011;33(9):987\u201395.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"1276_CR21","doi-asserted-by":"publisher","first-page":"535","DOI":"10.4161\/mabs.3.6.17815","volume":"3","author":"JM Benson","year":"2011","unstructured":"Benson JM, Peritt D, Scallon BJ, et al. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs. 2011;3(6):535\u201345.","journal-title":"MAbs."},{"key":"1276_CR22","doi-asserted-by":"crossref","unstructured":"Sandborn WJ, Feagan BG, Gasink C, et al. OC-057 A PH3 Randomised, multicenter, double blind, placebo (PBO)-controlled study of ustekinumab (UST) maintenance therapy in moderate-severe Crohn\u2019s disease (CD) PTS: Results from IM-UNITI. Gut. 2016;65(Suppl. 1):A32.2\u2013A34.","DOI":"10.1136\/gutjnl-2016-312388.56"},{"key":"1276_CR23","unstructured":"Sandborn WJ, Sands BE, Gasink C, et al. Sa1743\u2014Reduced rates of-Crohn\u2019s-related surgeries, hospitalizations and alternate biologic initiation with ustekinumab in the IM-UNITI study through 2\u00a0years. Gastroenterology. 2018;154(6, Suppl 1):S377\u20138."},{"issue":"4","key":"1276_CR24","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s11102-013-0506-0","volume":"17","author":"MS Broder","year":"2014","unstructured":"Broder MS, Neary MP, Chang E, Cherepanov D, Katznelson L. Treatments, complications, and healthcare utilization associated with acromegaly: a study in two large United States databases. Pituitary. 2014;17(4):333\u201341.","journal-title":"Pituitary"},{"key":"1276_CR25","unstructured":"Schepman PA, Knight T, Bond C, et al. Medical resource use in dermatomyositis\/polymyositis patients treated with adrenocorticotropic hormone. In: Presented at the 8th Annual Perspectives in Rheumatic Diseases Conference, Las Vegas, NV, September 18\u201319, 2015."},{"key":"1276_CR26","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s11102-013-0506-0","volume":"17","author":"MS Broder","year":"2014","unstructured":"Broder MS, Neary MP, Chang E, Katznelson L. Treatments, complications, and healthcare utilization associated with acromegaly: a study in two large United States databases. Pituitary. 2014;17:333\u201341.","journal-title":"Pituitary"},{"issue":"10","key":"1276_CR27","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1093\/oxfordjournals.aje.a009735","volume":"149","author":"CN Bernstein","year":"1999","unstructured":"Bernstein CN, Blanchard JF, Rawsthorne P, Wajda A. Epidemiology of Crohn\u2019s disease and ulcerative colitis in a central Canadian province: a population-based study. Am J Epidemiol. 1999;149(10):916\u201324.","journal-title":"Am J Epidemiol"},{"issue":"12","key":"1276_CR28","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/ajg.2011.304","volume":"106","author":"SY Shaw","year":"2011","unstructured":"Shaw SY, Blanchard JF, Bernstein CN. Association between the use of antibiotics and new diagnoses of Crohn\u2019s disease and ulcerative colitis. Am J Gastroenterol. 2011;106(12):2133\u201342.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"1276_CR29","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/j.1365-2559.2005.02248.x","volume":"48","author":"RK Yantiss","year":"2006","unstructured":"Yantiss RK, Odze RD. Diagnositc difficulties in inflammatory bowel disease pathology. Histopathology. 2006;48(2):116\u201332.","journal-title":"Histopathology"},{"issue":"6","key":"1276_CR30","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1002\/ibd.20361","volume":"14","author":"K Geboes","year":"2008","unstructured":"Geboes K, Colombel JF, Greenstein A, et al. Inderminate colitis: a review of the concept\u2014what\u2019s in a name? Inflamm Bowel Dis. 2008;14(6):850\u20137.","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"1276_CR31","doi-asserted-by":"publisher","first-page":"e0175099","DOI":"10.1371\/journal.pone.0175099","volume":"12","author":"H Patel","year":"2017","unstructured":"Patel H, Lissoos T, Rubin DT. Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn\u2019s disease in the United States. PLoS ONE. 2017;12(4):e0175099.","journal-title":"PLoS ONE"},{"key":"1276_CR32","doi-asserted-by":"publisher","first-page":"185","DOI":"10.2147\/DDDT.S11290","volume":"5","author":"JK Triantafillidis","year":"2011","unstructured":"Triantafillidis JK, Merikas E, Georgopoulos F. Current and emerging drugs for the treatment of inflammatory bowel disease. Drug Des Devel Ther. 2011;5:185\u2013210.","journal-title":"Drug Des Devel Ther."},{"issue":"22","key":"1276_CR33","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.3748\/wjg.v17.i22.2723","volume":"17","author":"AL San Rom\u00e1n","year":"2011","unstructured":"San Rom\u00e1n AL, Mu\u00f1oz F. Comorbidity in inflammatory bowel disease. World J Gastroenterol. 2011;17(22):2723\u201333.","journal-title":"World J Gastroenterol"},{"issue":"8","key":"1276_CR34","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1093\/ibd\/izz001","volume":"25","author":"C Chen","year":"2019","unstructured":"Chen C, Hartzema AG, Xiao H, et al. Real-world pattern of biologic use in patients with inflammatory bowel disease: treatment persistence, switching, and importance of concurrent immunosuppressive therapy. Inflamm Bowel Dis. 2019;25(8):1417\u201327.","journal-title":"Inflamm Bowel Dis"},{"key":"1276_CR35","unstructured":"Accessdata.fda.gov. [online]. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/761044lbl.pdf. Accessed 29 Jan 2020."},{"issue":"8","key":"1276_CR36","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1080\/03007995.2017.1335001","volume":"33","author":"TR Einarson","year":"2017","unstructured":"Einarson TR, Bereza BG, Lee XY, Lelli F. Dose escalation of biologics in Crohn\u2019s disease: critical review of observational studies. Curr Med Res Opin. 2017;33(8):1433\u201349.","journal-title":"Curr Med Res Opin"},{"key":"1276_CR37","doi-asserted-by":"publisher","first-page":"S351","DOI":"10.14309\/00000434-201810001-00617","volume":"113","author":"A Young","year":"2018","unstructured":"Young A, Tsistrakis S, Rubinov J, Kohan E, Hirten R, Ungaro R, Oikonomou I, et al. Ustekinumab dose intensification can be effective in Crohn\u2019s disease patients not responding to induction. Am J Gastroenterol. 2018;113:S351\u20132.","journal-title":"Am J Gastroenterol"},{"key":"1276_CR38","unstructured":"Obando C, Xie L, Vaidya N, Sah J. Evaluate the treatment patterns and healthcare utilizations for biologic therapies for Crohn\u2019s disease. In: Digestive disease week. Washington, DC: June 2\u20135, 2018."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01276-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-020-01276-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01276-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T01:30:50Z","timestamp":1616117450000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-020-01276-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,19]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["1276"],"URL":"https:\/\/doi.org\/10.1007\/s12325-020-01276-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,19]]},"assertion":[{"value":"11 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}